Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 25, 2024, titled "Jiangsu Alphamab Biopharmaceuticals, 3D Medicines (Beijing) and Glenmark announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World".
